November 29, 2011
Dooley MA, Jayne D, Ginzler EM, Isenberg D, Olsen NJ, Wofsy D, Eitner F, Appel GB, Contreras G, Lisk L, Solomons N, ALMS Group. N Engl J Med. 2011 Nov 17;365(20):1886-95
This 3-year randomized controlled trial compared mycophenolate mofetil and azathioprine as maintenance therapy after induction of remission in lupus nephritis. Mycophenolate mofetil was superior to azathioprine in achieving the primary end point, time to treatment failure, time to renal flare and time to rescue therapy There was a trend to fewer serious adverse events in [...]
February 8, 2011
Chen W, Tang X, Liu Q, Chen W, Fu P, Liu F, Liao Y, Yang Z, Zhang J, Chen J, Lou T, Fu J, Kong Y, Liu Z, Fan A, Rao S, Li Z, Yu X. Am J Kidney Dis. 2011 Feb;57(2):235-44
This multicenter noninferiority randomized controlled trial compared the efficacy and safety of tacrolimus versus intravenous cyclophosphamide as induction therapy for lupus nephritis. While limited by lack of blinding, small sample size, and short duration of follow-up, this study suggested that prednisone + tacrolimus achieved similar cumulative probabilities of complete remission and response than prednisone + [...]
December 26, 2010
Waldman M, Appel GB. Kidney Int. 2006 Oct;70(8):1403-12
This excellent review of lupus nephritis focuses on summarizing the most effective treatment for this condition while limiting therapy-induced toxicity. Free full text kindly provided by ASN.
January 11, 2010
Radhakrishnan J, Moutzouris DA, Ginzler EM, Solomons N, Siempos II, Appel GB. Kidney Int. 2010 Jan;77(2):152-60
Results of two randomized trial using induction treatment with either MMF or intravenous cyclophosphamide were pooled in this article. At 24 weeks, the results show that both groups were similar with respect to percentage change in proteinuria and serum creatinine as end points when used to treat patients with class V lupus.
October 18, 2009
Mak A, Cheak AA, Tan JY, Su HC, Ho RC, Lau CS. Rheumatology (Oxford). 2009 Aug;48(8):944-52
This meta-analysis suggests that for the treatment of proliferative lupus nephritis, MMF offers similar efficacy in renal remission and survival as cyclophosphamide with a better safety profile.
July 10, 2009
Boletis JN, Marinaki S, Skalioti C, Lionaki SS, Iniotaki A, Sfikakis PP. Nephrol Dial Transplant. 2009 Jul;24(7):2157-60
This prospective, observational study looked 10 women with subnephrotic proliferative lupus nephritis who relapsed on maintenance MMF or Imuran. They were treated with 4 weekly infusions of rituximab combined with MMF and prednisolone. This combination was found to have low toxicity and 7 patients were found to have a complete remission. This seems to warrant [...]
May 2, 2009
Appel GB, Contreras G, Dooley MA, Ginzler EM, Isenberg D, Jayne D, Li LS, Mysler E, Sánchez-Guerrero J, Solomons N, Wofsy D, Aspreva Lupus Management Study Group. J Am Soc Nephrol. 2009 May;20(5):1103-12
This study randomized 370 patients with class III to V lupus nephritis to MMF or intravenous cyclophosphamide during a 24-week induction period. Both groups received a tapering dose of prednisone. No difference in response rate was detected between groups.
April 1, 2009
Austin HA 3rd, Illei GG, Braun MJ, Balow JE. J Am Soc Nephrol. 2009 Apr;20(4):901-11
This study randomized patients with lupus membranous nephropathy to prednisone, cyclophosphamide or cyclosporine. Regimens containing cyclosporine or cyclophosphamide were each more effective than prednisone alone in inducing remission of proteinuria among such patients.
April 1, 2009
Beck LH Jr, Salant DJ. J Am Soc Nephrol. 2009 Apr;20(4):690-1
April 1, 2009
Mok CC. Nat Rev Nephrol. 2009 Apr;5(4):212-20
November 1, 2008
Szeto CC, Kwan BC, Lai FM, Tam LS, Li EK, Chow KM, Gang W, Li PK. Rheumatology (Oxford). 2008 Nov;47(11):1678-81
October 1, 2008
Bao H, Liu ZH, Xie HL, Hu WX, Zhang HT, Li LS. J Am Soc Nephrol. 2008 Oct;19(10):2001-10
October 1, 2008
Glassock RJ. J Am Soc Nephrol. 2008 Oct;19(10):1842-4
Recent Comments